Organizing Committee Member
Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis â€œNeuropsychiatric manifestations in patients with Systemic Lupus Erythematosusâ€ in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Full Research Professor. Dr. Stojanovichâ€™s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic Diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the â€œCURRENT CONTENTSâ€ or â€œScience citation indexâ€, like LUPUS REVIEWER DATABASE, Cellular and Molecular Neurobiology, The Journal of Vaccine < [email protected], The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of â€œthe European Forum on Antiphospholipid Antibodiesâ€, â€œMulticenter studies antiphospholipid antibodies, infections and autoimmune diseasesâ€. She is a mentor/ Supervisor ships a number of post-doc students. She was an Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars, and Symposia; the member of the Steering Committee of the â€œ(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)â€, and the Steering Committee of the â€œEULAR recommendations for the prevention and management of adult antiphospholipid syndrome". Professor Stojanovich is EULAR Honorary Member, and The Member of â€œThe International Team of Medical Experts for the Topic on antiphospholipid syndrome (Hughes Sy) and systemic lupus (INTERNATIONAL CHARITYâ€, The London Lupus Centre), she was the Chairman in the International Congress â€œAntiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definitionâ€, 2013, â€œGRANT 2015â€ of the EUROPEAN STROKE CONFERENCE Â» for â€œexcellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committeesâ€, and presented at the 24 th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company, MD, Ph.D., FRCP, is willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (â€œLillyâ€), in connection with the development of Tabalumab also was known as LY2439821. Co-Chairman and the lector â€œLUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of EULARÂ«: Belgrade, 18 TH march 2016, www.lupus-academy.org. Member of the American Association for the Advancement of Science (AAAS) from 2017; The Member of the international team of medical experts for the topic on APS (Hughes Sy).
ï‚· SYSTEMIC LUPUS ERYTHEMATOSUS ï‚· ANTIPHOSPHOLIPID SYNDROME ï‚· NEUROPSYCHIATRIC MANIFESTATIONS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE ï‚· VACCINATION IN PATIENTS WITH AUTO-IMMUNE INFLAMMATORY RHEUMATIC DISEASES